Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The urea cycle consists of a series of five main enzymes — carbamoyl phosphate synthetase 1 (CPS1), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL), and arginase 1 (ARG1) — working together primarily in the liver to convert highly toxic ammonia, a byproduct of amino acid catabolism, into the much less toxic urea for safe excretion by the kidneys. Additional supporting enzymes and transporters, such as N-acetylglutamate synthase (NAGS) and ornithine/citrulline antiporters, are involved in the cycle’s proper function. Genetic or acquired defects in these enzymes result in urea cycle disorders characterized by hyperammonemia, leading to serious neurological and systemic complications. Several drugs target this pathway by either activating defective enzymes or providing alternative routes for waste nitrogen excretion
Ammonia scavenging (drugs convert ammonia into excretable conjugates) Activation of N-acetylglutamate synthase (by carglumic acid)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Urea cycle enzyme.